Climb Bio Stock Fundamentals
| CLYM Stock | 1.95 0.08 3.94% |
Climb Bio fundamentals help investors to digest information that contributes to Climb Bio's financial success or failures. It also enables traders to predict the movement of Climb Stock. The fundamental analysis module provides a way to measure Climb Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Climb Bio stock.
At this time, Climb Bio's Research Development is very stable compared to the past year. As of the 21st of December 2024, Total Other Income Expense Net is likely to grow to about 562.8 K, while Selling General Administrative is likely to drop about 16.1 M. Climb | Select Account or Indicator |
Climb Bio Company Total Asset Analysis
Climb Bio's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Climb Bio Total Asset | 110.47 M |
Most of Climb Bio's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Climb Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Climb Total Asset Historical Pattern
Today, most investors in Climb Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Climb Bio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Climb Bio total asset as a starting point in their analysis.
Climb Bio Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Climb Total Assets
Total Assets |
|
Based on the latest financial disclosure, Climb Bio has a Total Asset of 110.47 M. This is 98.53% lower than that of the Healthcare sector and 94.41% lower than that of the Biotechnology industry. The total asset for all United States stocks is 99.63% higher than that of the company.
Climb Bio Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Climb Bio's current stock value. Our valuation model uses many indicators to compare Climb Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Climb Bio competition to find correlations between indicators driving Climb Bio's intrinsic value. More Info.Climb Bio is rated fifth in net income category among its peers. It is rated third in total debt category among its peers . Climb Bio reported last year Net Loss of (35.12 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Climb Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Climb Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Climb Bio's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Climb Bio could also be used in its relative valuation, which is a method of valuing Climb Bio by comparing valuation metrics of similar companies.Climb Bio is currently under evaluation in total asset category among its peers.
Climb Fundamentals
| Net Income | (35.12 M) | ||||
| Total Debt | 2.87 M | ||||
| Total Asset | 110.47 M | ||||
| Retained Earnings | (155.98 M) | ||||
| Working Capital | 107.42 M | ||||
| Net Asset | 110.47 M |
About Climb Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Climb Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Climb Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Climb Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Climb Bio Piotroski F Score and Climb Bio Altman Z Score analysis. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.